Donald Notman
Financieel Directeur/CFO bij OCULAR THERAPEUTIX, INC.
Vermogen: 328 289 $ op 30-04-2024
Profiel
Donald Notman is currently the Chief Financial Officer at Ocular Therapeutix, Inc. Prior to this, he was the Managing Director & Head-Private Capital Markets at Leerink Partners LLC.
From 2014 to 2017, he served as the Chief Financial Officer & Senior Vice President at Thrasos Therapeutics, Inc. Mr. Notman completed his undergraduate degree at Middlebury College and holds an MBA from the Tuck School of Business at Dartmouth.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
OCULAR THERAPEUTIX INC
0.05% | 31-03-2024 | 78 164 ( 0.05% ) | 328 289 $ | 30-04-2024 |
Actieve functies van Donald Notman
| Bedrijven | Functie | Begin |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Financieel Directeur/CFO | 25-09-2017 |
Eerdere bekende functies van Donald Notman
| Bedrijven | Functie | Einde |
|---|---|---|
Thrasos Therapeutics, Inc.
 Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Financieel Directeur/CFO | 01-03-2017 |
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Corporate Officer/Principal | - |
Opleiding van Donald Notman
| Middlebury College | Undergraduate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| OCULAR THERAPEUTIX, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Thrasos Therapeutics, Inc.
Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Finance |